{
  "@context": "https://schema.org",
  "@type": "Dataset",
  "name": "Supplement Brief Clinical Dose Registry",
  "description": "Curated trial dose floors for dietary supplement ingredients, extracted from Supplement Brief guides and interactive tools. Not medical advice.",
  "url": "https://supplementbrief.com/dataset/clinical-doses.json",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "creator": {
    "@type": "Organization",
    "name": "Supplement Brief",
    "url": "https://supplementbrief.com/"
  },
  "dateModified": "2026-08-18",
  "distribution": [
    {
      "@type": "DataDownload",
      "encodingFormat": "application/json",
      "contentUrl": "https://supplementbrief.com/dataset/clinical-doses.json"
    }
  ],
  "variableMeasured": [
    "Collagen peptides (hydrolyzed)",
    "Creatine monohydrate",
    "Dietary protein (complete)",
    "Korean red ginseng (Panax ginseng)",
    "L-arginine",
    "L-citrulline",
    "Maca root (Lepidium meyenii)",
    "Magnesium (elemental)",
    "Magnesium L-threonate",
    "Melatonin",
    "Omega-3 (EPA + DHA combined)",
    "Psyllium husk fibre",
    "Saffron (Crocus sativus) extract",
    "Urolithin A",
    "Vitamin B12 (cobalamin)"
  ],
  "hasPart": [
    {
      "slug": "collagen-peptides",
      "displayName": "Collagen peptides (hydrolyzed)",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "verisol-skin",
        "label": "Verisol skin trials (branded peptide)",
        "amount": 2.5,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "24401291",
          "23949208"
        ]
      },
      "trialFloors": [
        {
          "id": "verisol-skin",
          "label": "Verisol skin trials (branded peptide)",
          "presetLabel": "Verisol",
          "amount": 2.5,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "24401291",
            "23949208"
          ],
          "note": "Specific bioactive peptide preparation — generic 20 g powder is not equivalent evidence.",
          "effectDirection": "benefit"
        },
        {
          "id": "generic-range",
          "label": "Generic hydrolyzed collagen (instrumental skin trials)",
          "presetLabel": "Generic collagen",
          "amount": 2.5,
          "amountMax": 10,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "pmids": [],
          "note": "Pooled human skin trials often land in 2.5–10 g/day depending on preparation and endpoint.",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "collagen-peptides-for-skin",
        "collagen-loose-skin-after-ozempic"
      ],
      "ingredientGroups": [
        "Collagen"
      ],
      "shelfStats": {
        "registrySlug": "collagen-peptides",
        "label": "Collagen peptides (hydrolyzed)",
        "productCount": 2583,
        "medianPerServing": 1.9,
        "p25PerServing": 0.3,
        "p75PerServing": 8.2,
        "belowPrimaryFloorPct": 54,
        "abovePrimaryFloorPct": 41,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/collagen-peptides/"
    },
    {
      "slug": "creatine",
      "displayName": "Creatine monohydrate",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "maintenance",
        "label": "Maintenance (postmenopausal + training meta-analyses)",
        "amount": 3,
        "amountMax": 5,
        "unit": "g",
        "pmids": [
          "42141930"
        ]
      },
      "trialFloors": [
        {
          "id": "maintenance",
          "label": "Maintenance (postmenopausal + training meta-analyses)",
          "presetLabel": "Maintenance",
          "amount": 3,
          "amountMax": 5,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "42141930"
          ],
          "n": 608,
          "note": "Seven-RCT meta-analysis in postmenopausal women found +0.37 kg lean mass (95% CI +0.05 to +0.69). Most included trials used ≥5 g/day with resistance training; 3 g/day is a common maintenance floor.",
          "effectDirection": "benefit"
        },
        {
          "id": "bone-trial",
          "label": "Two-year bone trial dose (research)",
          "presetLabel": "Bone trial",
          "amount": 0.14,
          "unit": "g_per_kg",
          "frequency": "daily",
          "horizon": "2 years",
          "evidenceLevel": "limited",
          "pmids": [
            "37144634"
          ],
          "n": 237,
          "note": "~8–10 g at 60 kg. The primary endpoint failed — no effect on femoral neck, total hip or lumbar spine bone density over two years. Only secondary femoral-neck geometry (section modulus, buckling ratio) favoured creatine. This is a dose reference, not evidence that creatine builds bone.",
          "effectDirection": "null"
        }
      ],
      "guideSlugs": [
        "creatine-for-women-over-40",
        "glp-1-companion-supplements"
      ],
      "ingredientGroups": [
        "Creatine"
      ],
      "shelfStats": {
        "registrySlug": "creatine",
        "label": "Creatine monohydrate",
        "productCount": 2893,
        "medianPerServing": 3,
        "p25PerServing": 1.3,
        "p75PerServing": 5,
        "belowPrimaryFloorPct": 48,
        "abovePrimaryFloorPct": 39,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/creatine/"
    },
    {
      "slug": "protein",
      "displayName": "Dietary protein (complete)",
      "unit": "g",
      "doseKind": "daily_total",
      "primaryFloor": {
        "id": "glp1-weight-loss",
        "label": "GLP-1 / weight-loss lean-mass context",
        "amount": 1.2,
        "amountMax": 1.6,
        "unit": "g_per_kg",
        "pmids": [
          "42560932"
        ]
      },
      "trialFloors": [
        {
          "id": "glp1-weight-loss",
          "label": "GLP-1 / weight-loss lean-mass context",
          "presetLabel": "GLP-1 context",
          "amount": 1.2,
          "amountMax": 1.6,
          "unit": "g_per_kg",
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "42560932"
          ],
          "note": "Multiply body weight (kg) by 1.2–1.6 for grams per day — not a fixed gram dose. Use the protein target calculator.",
          "effectDirection": "benefit"
        },
        {
          "id": "example-70kg",
          "label": "Example at 70 kg (1.2–1.6 g/kg)",
          "presetLabel": "70 kg example",
          "amount": 84,
          "amountMax": 112,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [],
          "note": "Illustrative only — enter your weight in the protein calculator."
        }
      ],
      "guideSlugs": [
        "protein-for-glp1",
        "glp-1-companion-supplements",
        "hair-loss-after-weight-loss"
      ],
      "ingredientGroups": [],
      "shelfStats": null,
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/protein/"
    },
    {
      "slug": "panax-ginseng",
      "displayName": "Korean red ginseng (Panax ginseng)",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "krg-3g",
        "label": "1000 mg three times daily (de Andrade 2007)",
        "amount": 3,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "16855773"
        ]
      },
      "trialFloors": [
        {
          "id": "krg-3g",
          "label": "1000 mg three times daily (de Andrade 2007)",
          "presetLabel": "de Andrade 2007",
          "amount": 3,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "16855773"
          ],
          "n": 60,
          "note": "IIEF-5 rose from 16.4 to 21.0 against no change on placebo, and 66.6% reported improved erection. Testosterone, prolactin and cholesterol were unchanged, so this is not a hormonal mechanism. Single centre, mild to mild-moderate ED only.",
          "effectDirection": "benefit"
        },
        {
          "id": "krg-2700mg",
          "label": "900 mg three times daily (Hong 2002)",
          "presetLabel": "Hong 2002",
          "amount": 2.7,
          "frequency": "daily",
          "horizon": "8 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "12394711"
          ],
          "n": 45,
          "note": "Double-blind crossover with an 8-week washout design. IIEF total and RigiScan penile tip rigidity both improved; 60% reported better erections. Explicitly published as a preliminary report.",
          "palette": "research",
          "effectDirection": "benefit"
        },
        {
          "id": "cochrane-pooled",
          "label": "Cochrane pooled estimate (effect rated trivial)",
          "presetLabel": "Lee 2021",
          "amount": 3,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "33871063"
          ],
          "n": 587,
          "note": "Nine RCTs, 587 men. Pooled IIEF-15 erectile-function difference was 3.52 points against a minimal clinically important difference of 4, and IIEF-5 was 2.39 points — Cochrane called the effect trivial at low-to-moderate certainty. The dose is real; the benefit at that dose is small on average.",
          "palette": "research",
          "effectDirection": "null"
        }
      ],
      "guideSlugs": [
        "panax-ginseng-for-ed",
        "how-to-read-supplement-label"
      ],
      "ingredientGroups": [
        "Ginseng"
      ],
      "shelfStats": {
        "registrySlug": "panax-ginseng",
        "label": "Korean red ginseng (Panax ginseng)",
        "productCount": 1377,
        "medianPerServing": 0.1,
        "p25PerServing": 0,
        "p75PerServing": 0.2,
        "belowPrimaryFloorPct": 100,
        "abovePrimaryFloorPct": 0,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/panax-ginseng/"
    },
    {
      "slug": "l-arginine",
      "displayName": "L-arginine",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "menafra-2022",
        "label": "Menafra 2022 (vasculogenic ED)",
        "amount": 6,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "34973154"
        ]
      },
      "trialFloors": [
        {
          "id": "menafra-2022",
          "label": "Menafra 2022 (vasculogenic ED)",
          "presetLabel": "Menafra 2022",
          "amount": 6,
          "frequency": "daily",
          "horizon": "3 months",
          "evidenceLevel": "medium",
          "pmids": [
            "34973154"
          ],
          "n": 98,
          "note": "Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "l-citrulline-vs-l-arginine-for-ed",
        "nitric-oxide-ed-supplements",
        "supplements-for-ssri-induced-ed"
      ],
      "ingredientGroups": [
        "Arginine"
      ],
      "shelfStats": {
        "registrySlug": "l-arginine",
        "label": "L-arginine",
        "productCount": 3121,
        "medianPerServing": 0.8,
        "p25PerServing": 0.3,
        "p75PerServing": 1.5,
        "belowPrimaryFloorPct": 99,
        "abovePrimaryFloorPct": 1,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/l-arginine/"
    },
    {
      "slug": "l-citrulline",
      "displayName": "L-citrulline",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "cormio-2011",
        "label": "Cormio 2011 pilot (mild ED)",
        "amount": 1.5,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "21195829"
        ]
      },
      "trialFloors": [
        {
          "id": "cormio-2011",
          "label": "Cormio 2011 pilot (mild ED)",
          "presetLabel": "Cormio 2011",
          "amount": 1.5,
          "frequency": "daily",
          "horizon": "1 month",
          "evidenceLevel": "limited",
          "pmids": [
            "21195829"
          ],
          "n": 24,
          "note": "Single-blind pilot; 95% CI not reported in primary paper.",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "l-citrulline-vs-l-arginine-for-ed",
        "nitric-oxide-ed-supplements",
        "supplements-for-ssri-induced-ed"
      ],
      "ingredientGroups": [
        "Citrulline"
      ],
      "shelfStats": {
        "registrySlug": "l-citrulline",
        "label": "L-citrulline",
        "productCount": 2818,
        "medianPerServing": 3,
        "p25PerServing": 1,
        "p75PerServing": 6,
        "belowPrimaryFloorPct": 32,
        "abovePrimaryFloorPct": 64,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/l-citrulline/"
    },
    {
      "slug": "maca",
      "displayName": "Maca root (Lepidium meyenii)",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "aisd-women-3g",
        "label": "Antidepressant-induced sexual dysfunction, women",
        "amount": 3,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "25954318"
        ]
      },
      "trialFloors": [
        {
          "id": "aisd-women-3g",
          "label": "Antidepressant-induced sexual dysfunction, women",
          "presetLabel": "Women 3 g",
          "amount": 3,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "25954318"
          ],
          "n": 42,
          "note": "Placebo-controlled, 45 women on SSRIs or SNRIs randomised. Remission favoured maca but stayed low in absolute terms — 9.5% vs 4.8% by ASEX and 30% vs 20% by MGH-SFQ — and the benefit clustered in postmenopausal women. Women only; there is no male equivalent of this trial.",
          "palette": "feminine",
          "effectDirection": "benefit"
        },
        {
          "id": "dose-finding-arms",
          "label": "Dose-finding pilot, 1.5 g arm failed",
          "presetLabel": "Dose-finding",
          "amount": 1.5,
          "amountMax": 3,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "pmids": [
            "18801111"
          ],
          "n": 16,
          "note": "Head-to-head 1.5 g/day vs 3.0 g/day in 20 remitted depressed outpatients, 17 of them women. Only the 3.0 g arm improved significantly on ASEX and MGH-SFQ; 1.5 g/day did not separate. Ten completers. This is the entry's evidence that the lower dose is below the floor, not above it.",
          "palette": "research",
          "effectDirection": "null"
        },
        {
          "id": "men-subjective-2400mg",
          "label": "Men with mild ED, subjective wellbeing",
          "presetLabel": "Men 2.4 g",
          "amount": 2.4,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "19260845"
          ],
          "n": 50,
          "note": "The only randomised maca trial in men, and it was mild general ED rather than antidepressant-induced. Both arms improved; maca improved more, but IIEF-5 gained only 1.6 points vs 0.5 on placebo — far below the roughly 4-point threshold for a change men notice. The paper frames its own outcome as subjective wellbeing.",
          "palette": "research",
          "effectDirection": "secondary-only"
        }
      ],
      "guideSlugs": [
        "supplements-for-ssri-induced-ed"
      ],
      "ingredientGroups": [
        "Maca"
      ],
      "shelfStats": {
        "registrySlug": "maca",
        "label": "Maca root (Lepidium meyenii)",
        "productCount": 1239,
        "medianPerServing": 0.3,
        "p25PerServing": 0.1,
        "p75PerServing": 0.6,
        "belowPrimaryFloorPct": 94,
        "abovePrimaryFloorPct": 4,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/maca/"
    },
    {
      "slug": "magnesium",
      "displayName": "Magnesium (elemental)",
      "unit": "mg",
      "doseKind": "elemental",
      "primaryFloor": {
        "id": "repletion-daily",
        "label": "Form-comparison trial (elemental)",
        "amount": 300,
        "amountMax": null,
        "unit": "mg",
        "pmids": [
          "14596323"
        ]
      },
      "trialFloors": [
        {
          "id": "rda-female",
          "label": "Daily value (women)",
          "presetLabel": "Women DV",
          "amount": 320,
          "frequency": "daily",
          "evidenceLevel": "high",
          "pmids": [],
          "note": "FDA daily value reference — not a trial dose.",
          "palette": "feminine"
        },
        {
          "id": "rda-male",
          "label": "Daily value (men)",
          "presetLabel": "Men DV",
          "amount": 420,
          "frequency": "daily",
          "evidenceLevel": "high",
          "pmids": [],
          "note": "FDA daily value reference — not a trial dose.",
          "palette": "maintenance"
        },
        {
          "id": "repletion-daily",
          "label": "Form-comparison trial (elemental)",
          "presetLabel": "Form comparison",
          "amount": 300,
          "frequency": "daily",
          "horizon": "60 days",
          "evidenceLevel": "medium",
          "pmids": [
            "14596323"
          ],
          "n": 46,
          "note": "300 mg elemental per day compared citrate, amino-acid chelate and oxide in healthy adults. The endpoint was absorption (urinary, serum, salivary magnesium), not a symptom — oxide did not separate from placebo.",
          "palette": "research",
          "effectDirection": "benefit"
        },
        {
          "id": "sleep-symptom",
          "label": "Bisglycinate sleep trial (elemental)",
          "presetLabel": "Sleep trial",
          "amount": 250,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "40918053"
          ],
          "n": 155,
          "note": "250 mg elemental as bisglycinate beat placebo on Insomnia Severity Index at week 4, but the effect was small (Cohen's d = 0.2) and concentrated in people with low dietary magnesium intake.",
          "palette": "research",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "magnesium-forms-compared",
        "electrolytes-on-ozempic",
        "glp-1-companion-supplements"
      ],
      "ingredientGroups": [
        "Magnesium"
      ],
      "shelfStats": {
        "registrySlug": "magnesium",
        "label": "Magnesium (elemental)",
        "productCount": 27926,
        "medianPerServing": 100,
        "p25PerServing": 35,
        "p75PerServing": 200,
        "belowPrimaryFloorPct": 85,
        "abovePrimaryFloorPct": 12,
        "unit": "mg",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/magnesium/"
    },
    {
      "slug": "magnesium-l-threonate",
      "displayName": "Magnesium L-threonate",
      "unit": "mg",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "cognition-sleep-2g",
        "label": "Cognition and sleep trial (compound weight)",
        "amount": 2000,
        "amountMax": null,
        "unit": "mg",
        "pmids": [
          "41601871"
        ]
      },
      "trialFloors": [
        {
          "id": "cognition-sleep-2g",
          "label": "Cognition and sleep trial (compound weight)",
          "presetLabel": "Magtein 2 g",
          "amount": 2000,
          "frequency": "daily",
          "horizon": "6 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "41601871"
          ],
          "n": 100,
          "note": "2 g/day of branded Magtein in adults aged 18-45 reporting unsatisfying sleep. Overall cognition improved (NIH Total Cognition Composite, p = 0.043) along with reaction time, resting heart rate and HRV. Raven's matrices did not change, and neither did objective sleep from a wearable — only self-reported sleep-related impairment.",
          "effectDirection": "secondary-only"
        }
      ],
      "guideSlugs": [
        "magnesium-forms-compared"
      ],
      "ingredientGroups": [
        "Magnesium"
      ],
      "shelfStats": {
        "registrySlug": "magnesium-l-threonate",
        "label": "Magnesium L-threonate",
        "productCount": 152,
        "medianPerServing": 2000,
        "p25PerServing": 1000,
        "p75PerServing": 2000,
        "belowPrimaryFloorPct": 41,
        "abovePrimaryFloorPct": 14,
        "unit": "mg",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/magnesium-l-threonate/"
    },
    {
      "slug": "melatonin",
      "displayName": "Melatonin",
      "unit": "mg",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "dswpd-half-mg",
        "label": "Delayed sleep-wake phase disorder, 0.5 mg timed",
        "amount": 0.5,
        "amountMax": null,
        "unit": "mg",
        "pmids": [
          "29912983"
        ]
      },
      "trialFloors": [
        {
          "id": "dswpd-half-mg",
          "label": "Delayed sleep-wake phase disorder, 0.5 mg timed",
          "presetLabel": "Sletten 2018",
          "amount": 0.5,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "medium",
          "pmids": [
            "29912983"
          ],
          "n": 116,
          "note": "0.5 mg fast-release taken one hour before the desired bedtime, alongside behavioural sleep-wake scheduling in both arms. Sleep onset moved 34 minutes earlier (95% CI −60 to −8) and 52.8% improved on clinician rating vs 24.0% on placebo. The scheduling was part of the treatment — this is not a melatonin-alone result.",
          "effectDirection": "benefit"
        },
        {
          "id": "phase-advance-low",
          "label": "Circadian phase advance, timing over dose",
          "presetLabel": "Mundey 2005",
          "amount": 0.3,
          "amountMax": 3,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "16295212"
          ],
          "n": 13,
          "note": "0.3 mg and 3.0 mg advanced circadian phase by the same amount. What predicted the size of the shift was when the dose was taken relative to dim-light melatonin onset (r² = 0.94), not how much was taken. Thirteen subjects.",
          "palette": "research",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "winter-blues-supplements"
      ],
      "ingredientGroups": [
        "Melatonin"
      ],
      "shelfStats": {
        "registrySlug": "melatonin",
        "label": "Melatonin",
        "productCount": 2662,
        "medianPerServing": 3,
        "p25PerServing": 2,
        "p75PerServing": 5,
        "belowPrimaryFloorPct": 3,
        "abovePrimaryFloorPct": 95,
        "unit": "mg",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/melatonin/"
    },
    {
      "slug": "omega-3",
      "displayName": "Omega-3 (EPA + DHA combined)",
      "unit": "g",
      "doseKind": "epa_dha",
      "primaryFloor": {
        "id": "otc-inflammatory",
        "label": "OTC inflammatory-marker meta-analyses (EPA+DHA)",
        "amount": 1,
        "amountMax": 2,
        "unit": "g",
        "pmids": [
          "24505395",
          "35914448"
        ]
      },
      "trialFloors": [
        {
          "id": "otc-inflammatory",
          "label": "OTC inflammatory-marker meta-analyses (EPA+DHA)",
          "presetLabel": "OTC EPA+DHA",
          "amount": 1,
          "amountMax": 2,
          "frequency": "daily",
          "evidenceLevel": "medium",
          "pmids": [
            "24505395",
            "35914448"
          ],
          "note": "Active dose is EPA + DHA on the Supplement Facts panel — not total fish oil weight. This range is the span of doses pooled across 68 RCTs and 32 meta-analyses; neither review identifies a single threshold dose, and the CRP effect weakened above BMI 30.",
          "effectDirection": "benefit"
        },
        {
          "id": "epa-inflammatory-mdd",
          "label": "EPA dose-finding in inflammatory depression",
          "presetLabel": "EPA 4 g (MDD)",
          "amount": 4,
          "frequency": "daily",
          "horizon": "12 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "36005883"
          ],
          "n": 45,
          "note": "EPA-only, in adults with major depression plus BMI over 25 and hs-CRP at or above 3 mg/L. Response was 64% vs 40% on placebo (Cohen d = 0.53) but not statistically significant, and the prespecified IL-6 and TNF endpoints were missed. A dose-finding signal in a narrow phenotype, not an established dose.",
          "palette": "research",
          "effectDirection": "null"
        },
        {
          "id": "prescription-epa",
          "label": "REDUCE-IT (prescription icosapent ethyl)",
          "presetLabel": "REDUCE-IT",
          "amount": 4,
          "frequency": "daily",
          "evidenceLevel": "high",
          "pmids": [
            "30415628"
          ],
          "note": "Prescription purified EPA — not comparable to a standard fish oil capsule.",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "omega-3-for-inflammation",
        "winter-blues-supplements"
      ],
      "ingredientGroups": [
        "Fish Oil",
        "Omega-3 Fatty Acids"
      ],
      "shelfStats": {
        "registrySlug": "omega-3",
        "label": "Omega-3 (EPA + DHA combined)",
        "productCount": 7305,
        "medianPerServing": 0.6,
        "p25PerServing": 0.2,
        "p75PerServing": 0.9,
        "belowPrimaryFloorPct": 76,
        "abovePrimaryFloorPct": 19,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/omega-3/"
    },
    {
      "slug": "psyllium",
      "displayName": "Psyllium husk fibre",
      "unit": "g",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "weight-loss-meta",
        "label": "Weight-loss meta-analysis (mean dose, before meals)",
        "amount": 10.8,
        "amountMax": null,
        "unit": "g",
        "pmids": [
          "37163454"
        ]
      },
      "trialFloors": [
        {
          "id": "weight-loss-meta",
          "label": "Weight-loss meta-analysis (mean dose, before meals)",
          "presetLabel": "Weight-loss meta",
          "amount": 10.8,
          "frequency": "daily",
          "horizon": "4-5 months",
          "evidenceLevel": "medium",
          "pmids": [
            "37163454"
          ],
          "n": 354,
          "note": "Six RCTs in overweight and obese adults. Body weight fell 2.1 kg (95% CI −2.6 to −1.6), BMI 0.8 kg/m² and waist circumference 2.2 cm. 10.8 g/day is the mean dose across those trials, taken just before meals over a mean 4.8 months — the timing is part of the protocol, not a detail.",
          "effectDirection": "benefit"
        }
      ],
      "guideSlugs": [
        "supplements-for-mirtazapine-weight-gain",
        "glp-1-companion-supplements"
      ],
      "ingredientGroups": [
        "Psyllium"
      ],
      "shelfStats": {
        "registrySlug": "psyllium",
        "label": "Psyllium husk fibre",
        "productCount": 762,
        "medianPerServing": 1,
        "p25PerServing": 0.3,
        "p75PerServing": 3,
        "belowPrimaryFloorPct": 98,
        "abovePrimaryFloorPct": 2,
        "unit": "g",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/psyllium/"
    },
    {
      "slug": "saffron",
      "displayName": "Saffron (Crocus sativus) extract",
      "unit": "mg",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "aisd-men",
        "label": "Fluoxetine-related sexual dysfunction, men",
        "amount": 30,
        "amountMax": null,
        "unit": "mg",
        "pmids": [
          "22552758"
        ]
      },
      "trialFloors": [
        {
          "id": "aisd-men",
          "label": "Fluoxetine-related sexual dysfunction, men",
          "presetLabel": "Men (AISD)",
          "amount": 30,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "22552758"
          ],
          "n": 30,
          "note": "15 mg twice daily in men whose depression was already stabilised on fluoxetine. Erectile function and intercourse satisfaction improved; orgasmic function, overall satisfaction and desire did not. Thirty completers in a single Iranian centre.",
          "effectDirection": "benefit"
        },
        {
          "id": "aisd-women",
          "label": "Fluoxetine-related sexual dysfunction, women",
          "presetLabel": "Women (AISD)",
          "amount": 30,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "23280545"
          ],
          "n": 34,
          "note": "Same 30 mg/day in women stabilised on fluoxetine 40 mg. Total FSFI, arousal, lubrication and pain improved; desire did not. Separate trial, separate instrument — do not read the men's result into this one or the reverse.",
          "palette": "feminine",
          "effectDirection": "benefit"
        },
        {
          "id": "postpartum-vs-fluoxetine",
          "label": "Postpartum depression, saffron vs fluoxetine",
          "presetLabel": "Postpartum",
          "amount": 30,
          "frequency": "daily",
          "horizon": "6 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "27595298"
          ],
          "n": 64,
          "note": "15 mg twice daily against fluoxetine 20 mg twice daily in mild-to-moderate postpartum depression. There was no significant difference between arms, and complete response was 40.6% on saffron vs 50.0% on fluoxetine — an active-comparator trial with no placebo arm, so it does not establish that saffron beat nothing.",
          "palette": "research",
          "effectDirection": "null"
        },
        {
          "id": "depression-meta",
          "label": "Depression meta-analyses (pooled)",
          "presetLabel": "Depression meta",
          "amount": 30,
          "frequency": "daily",
          "evidenceLevel": "limited",
          "pmids": [
            "24299602",
            "31118846"
          ],
          "note": "Pooled saffron-vs-placebo effect was large but the confidence interval reached zero (SMD −0.86, 95% CI −1.73 to 0.00), and saffron did not differ from fluoxetine. Eight small trials, most from a single country. Treat 30 mg/day as the dose those trials used, not as a settled effective dose.",
          "palette": "research",
          "effectDirection": "null"
        }
      ],
      "guideSlugs": [
        "supplements-for-ssri-induced-ed",
        "winter-blues-supplements"
      ],
      "ingredientGroups": [
        "Saffron"
      ],
      "shelfStats": {
        "registrySlug": "saffron",
        "label": "Saffron (Crocus sativus) extract",
        "productCount": 250,
        "medianPerServing": 30,
        "p25PerServing": 20,
        "p75PerServing": 89,
        "belowPrimaryFloorPct": 46,
        "abovePrimaryFloorPct": 39,
        "unit": "mg",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/saffron/"
    },
    {
      "slug": "urolithin-a",
      "displayName": "Urolithin A",
      "unit": "mg",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "atlas-branded",
        "label": "ATLAS trial, branded Mitopure",
        "amount": 500,
        "amountMax": 1000,
        "unit": "mg",
        "pmids": [
          "35584623"
        ]
      },
      "trialFloors": [
        {
          "id": "atlas-branded",
          "label": "ATLAS trial, branded Mitopure",
          "presetLabel": "ATLAS 500 mg",
          "amount": 500,
          "amountMax": 1000,
          "frequency": "daily",
          "horizon": "4 months",
          "evidenceLevel": "limited",
          "pmids": [
            "35584623"
          ],
          "note": "Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.",
          "effectDirection": "secondary-only"
        },
        {
          "id": "older-adults-1g",
          "label": "Older adults, 1000 mg",
          "presetLabel": "Liu 2022",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "4 months",
          "evidenceLevel": "limited",
          "pmids": [
            "35050355"
          ],
          "n": 66,
          "note": "Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated.",
          "palette": "research",
          "effectDirection": "null"
        },
        {
          "id": "safety-biology",
          "label": "Safety and mitochondrial gene signature",
          "presetLabel": "Andreux 2019",
          "amount": 500,
          "amountMax": 1000,
          "frequency": "daily",
          "horizon": "4 weeks",
          "evidenceLevel": "limited",
          "pmids": [
            "32694802"
          ],
          "n": 60,
          "note": "Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers \"does oral urolithin A do anything in tissue\", not \"will I be stronger\".",
          "palette": "research",
          "effectDirection": "null"
        }
      ],
      "guideSlugs": [
        "urolithin-a-vs-nmn"
      ],
      "ingredientGroups": [
        "Urolithin A"
      ],
      "shelfStats": null,
      "updatedDate": "2026-08-18",
      "dosePageUrl": "https://supplementbrief.com/dose/urolithin-a/"
    },
    {
      "slug": "vitamin-b12",
      "displayName": "Vitamin B12 (cobalamin)",
      "unit": "mcg",
      "doseKind": "compound",
      "primaryFloor": {
        "id": "repletion-oral",
        "label": "Oral repletion (deficiency confirmed)",
        "amount": 1000,
        "amountMax": null,
        "unit": "mcg",
        "pmids": [
          "33513879",
          "29543316"
        ]
      },
      "trialFloors": [
        {
          "id": "repletion-oral",
          "label": "Oral repletion (deficiency confirmed)",
          "presetLabel": "Repletion",
          "amount": 1000,
          "frequency": "daily",
          "horizon": "1 year",
          "evidenceLevel": "medium",
          "pmids": [
            "33513879",
            "29543316"
          ],
          "n": 90,
          "note": "1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight.",
          "effectDirection": "benefit"
        },
        {
          "id": "multivitamin-trap",
          "label": "Typical multivitamin (not therapeutic)",
          "presetLabel": "Multivitamin",
          "amount": 6,
          "amountMax": 25,
          "frequency": "daily",
          "evidenceLevel": "high",
          "pmids": [],
          "note": "Illustrative floor only — not sufficient for metformin-associated deficiency repletion."
        }
      ],
      "guideSlugs": [
        "metformin-b12-deficiency-which-form"
      ],
      "ingredientGroups": [
        "Vitamin B12"
      ],
      "shelfStats": {
        "registrySlug": "vitamin-b12",
        "label": "Vitamin B12 (cobalamin)",
        "productCount": 27296,
        "medianPerServing": 50,
        "p25PerServing": 9,
        "p75PerServing": 200,
        "belowPrimaryFloorPct": 90,
        "abovePrimaryFloorPct": 4,
        "unit": "mcg",
        "generatedAt": "2026-08-18T10:06:58.533Z",
        "source": "NIH DSLD bulk CSV (DietarySupplementFacts)"
      },
      "updatedDate": "2026-08-10",
      "dosePageUrl": "https://supplementbrief.com/dose/vitamin-b12/"
    }
  ]
}